To summarise the results:
- All three trials showed that RYONCIL (remestemcel-L) demonstrated safety and efficacy in patients with the greatest level of inflammation and most severe GVHD.
- Study 275 used RYONCIL as a salvage treatment for 241 children exhibiting acute GVHD who failed to respond to steroids and a range of other treatments, with 67% overall survival at Day 100. This is compared to 10% survival in severe forms of acute GVHD cases with standard care.
- Study GVHD001/002 used RYONCIL as a first line treatment for 55 children exhibiting acute GVHD who failed to respond to steroid treatments, with 74.1% survival at Day 100 and 68.5% overall survival at Day 180. This is compared to 57% survival rate at Day 100 for a matched placebo group from a Mount Sinai database with standard care.
- Study 280 used RYONCIL as a second line treatment for 232 adults and 28 children with steroid-refractory acute GVHD who failed to respond to steroid treatment. At Day 28 overall survival rate of 57% compared to placebo at 37%. At Day 28 overall survival rate for children was 64% compared to placebo at 36%. Adults did not respond as well as children to the treatment.
Conclusion: RYONCIL works well for children and high risk adults with acute steroid-refractory GVHD, but there was no significant benefit of using RYONCIL in standard risk patients. There is currently no FDA approved treatment for children with steroid-refractory acute GVHD in the USA.
Dr Jacques Galipeau concluded that “after more than a decade of clinical study involving three distinctadvanced trials, it appears that remestemcel-L might well have finally met theregulatory requirements for marketing approval in the United States forsteroid-refractory acute GVHD in children”.
- Forums
- ASX - By Stock
- MSB
- Ann: 3 Articles on RYONCIL GvHD Trial Results Published in BBMT
Ann: 3 Articles on RYONCIL GvHD Trial Results Published in BBMT, page-29
-
-
- There are more pages in this discussion • 99 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.01 |
Change
-0.065(6.07%) |
Mkt cap ! $1.147B |
Open | High | Low | Value | Volume |
$1.05 | $1.05 | 99.5¢ | $9.449M | 9.298M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 64999 | $1.01 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.02 | 64541 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 64999 | 1.005 |
7 | 58759 | 1.000 |
13 | 162397 | 0.995 |
23 | 402743 | 0.990 |
10 | 194198 | 0.985 |
Price($) | Vol. | No. |
---|---|---|
1.020 | 64541 | 3 |
1.025 | 71041 | 4 |
1.030 | 154979 | 5 |
1.035 | 90341 | 5 |
1.040 | 32541 | 1 |
Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online